Secretory Phospholipase A2-IIA and Cardiovascular Disease
Open Access
- 31 July 2013
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 62 (21), 1966-1976
- https://doi.org/10.1016/j.jacc.2013.06.044
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) TrialCardiovascular Drugs and Therapy, 2011
- Prognostic Utility of Secretory Phospholipase A2 in Patients with Stable Coronary Artery DiseaseClinical Chemistry, 2011
- Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver TissuePLoS Genetics, 2011
- The sPLA 2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) TrialCirculation, 2010
- Biological, clinical and population relevance of 95 loci for blood lipidsNature, 2010
- Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE− / − MiceJournal of Cardiovascular Pharmacology, 2009
- Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and WomenArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS studyHuman Molecular Genetics, 2005
- Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stressJournal of Lipid Research, 2005